

SAFETY ANALYSIS OF DOSE-DENSE CHEMOTHERAPY IN BREAST CANCER TREATMENT

Paradela García, E; Ponce González, A; Corriente Gordon, I; Camacho Parreño, S

Hospital Pharmacy. Juan Ramon Jimenez University Hospital. Ronda Norte Avenue, n/n, 21005 Huelva, Spain.

BACKGROUND AND IMPORTANCE

Dose-dense (DD) chemotherapy has been incorporated into breast cancer management with the objective of enhancing therapeutic efficacy by **reducing administration intervals** to two weeks, without increasing cumulative dose or toxicity.


AIM AND OBJECTIVES

This study evaluates the **safety profile** of the **epirubicin-cyclophosphamide (EC)** followed by **paclitaxel (P)**, both given in DD regimens, used as neoadjuvant or adjuvant therapy.

MATERIAL AND METHODS


A retrospective observational study was conducted in a tertiary hospital including patients treated between **January 2024 and September 2025**. Collected data included demographic characteristics, disease stage, treatment type, number of cycles administered, treatment completion, delays or dose reductions, and adverse events (Aes). Data sources were the electronic health record Diraya® and the prescription system Farmis_Oncofarm®.

RESULTS



Treatment modifications during chemotherapy

Treatment phase	Modification type	n	Main reason
EC	Cycle delay	8	Infections
Paclitaxel	Cycle delay	5	Myelotoxicity
EC	Dose reduction	7	Asthenia or nausea
Paclitaxel	Dose reduction	16	Neurotoxicity
EC	Discontinuation	1	Ischemia
Paclitaxel	Discontinuation	11	Infusional reaction



CONCLUSION AND RELEVANCE

In conclusion, **gastrointestinal toxicity** and **asthenia** were more frequent during EC, whereas **neurotoxicity** predominated with P. **Myelotoxicity** was the main cause of cycle delays despite prophylactic administration of colony-stimulating factors. Although the absence of a comparator and limited sample size restrict generalizability, the findings support that DD chemotherapy exhibits an **acceptable and manageable safety profile** in breast cancer.

5PSQ-070

